Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases

Anti-Cancer Drugs

Volumn 20, Issue 8, 2009, Pages 752-756

  Fushida, Sachio ^a   Fujimura, Takashi ^a   Oyama, Katsunobu ^a   Yagi, Yasumichi ^a   Kinoshita, Jun ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARAAORTIC LYMPH NODE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; STOMACH CANCER; TOXICITY TESTING; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OXONIC ACID; STOMACH; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 70349319843     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832ec02b     Document Type: Article

References (16)

1. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Froup study 9501. J Clin Oncol 2004; 22:2767-2773.
2. Yonemura Y, Katayama K, Kamata T, Fushida S, Segawa M, Ooyama S, et al. Surgical treatment of advanced gastric cancer with metastasis in para-aortic lymph node. Int Surg 1991; 76:222-225.
3. Isozaki H, Okajima K, Fujii K, Nomura E, Izumi N, Mabuchi H, et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 1999; 46:549-554.
4. Kunisaki C, Shimada H, Yamaoka H, Wakasugi J, Takahashi M, Akiyama H, et al. Significance of para-aortic lymph node dissection in advanced gastric cancer. Hepatogastroenterology 1999; 46:2635-2642.
5. Nakajima T, Ohta K, Ishihara S, Oyama S, Nishi M, Ohashi Y, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 1997; 4:203-208.
6. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
7. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxanic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53:4004-4009.
8. Sugimachi K, Maehara Y. The S-1 gastrointestinal cancer study group: an early phase II study of oral S-1, a newly developed 5-fluorouracil delivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57:202-210.
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegaful-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
10. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007; 109:33-40.
11. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12:3042-3047.
12. Takayama T, Sato Y, Sagawa T, Okamoto T, Nagashima H, Takahashi Y, et al. Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 2007; 97:851-856.
13. Nakayama N, Koizumi W, Sasaki T, Higuchi K, Tanabe S, Nishimura K, et al. A multicenter phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 2008; 75:1-7
14. Japanese Research Society for Gastric Cancer. Response assessment of chemotherapy and radiotherapy for gastric carcinoma part IV. In: Nishi M, Omori Y, Miwa K, editors. Japanese classification gastric carcinoma. 1st ed. Tokyo: Kanehara; 1995. pp. 89-100.
15. Yoshikawa T, Sasako M, Sano T, Nashimoto A, Kurita A, Tsujinaka T, et al. Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from results prospective randomized controlled trial. Br J Surg 2006; 93:1526-1529.
16. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359:453-462.